Next Article in Journal
Mucosal Vaccination via the Respiratory Tract
Next Article in Special Issue
Rational Development of Liposomal Hydrogels: A Strategy for Topical Vaginal Antiretroviral Drug Delivery in the Context of HIV Prevention
Previous Article in Journal
Scale-Up Synthesis and In Vivo Anti-Tumor Activity of Curcumin Diethyl Disuccinate, an Ester Prodrug of Curcumin, in HepG2-Xenograft Mice
Previous Article in Special Issue
17-α Hydroxyprogesterone Nanoemulsifying Preconcentrate-Loaded Vaginal Tablet: A Novel Non-Invasive Approach for the Prevention of Preterm Birth
Open AccessReview

Topical Inserts: A Versatile Delivery Form for HIV Prevention

CONRAD, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Arlington, VA 22209, USA
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(8), 374;
Received: 30 June 2019 / Revised: 21 July 2019 / Accepted: 23 July 2019 / Published: 1 August 2019
(This article belongs to the Special Issue Vaginal Drug Delivery for Local and Systemic Applications)
The development of topical inserts for the prevention of sexually transmitted infections (STIs), particularly human immunodeficiency virus (HIV), represents a promising alternative to oral and parenteral pre-exposure prophylaxis (PrEP) dosage forms. They may be used for vaginal and/or rectal administration of a variety of agents with antiviral activity. Topical inserts deliver drugs to the portal of viral entry, i.e., the genital or rectal mucosa, with low systemic exposure, and therefore are safer and have fewer side effects than systemic PrEP agents. They may dissolve fast, releasing the active drugs within minutes of insertion, or slowly for long-acting drug delivery. Furthermore, they are user-friendly being easy to administer, discreet and highly portable. They are also economical and easy to manufacture at scale and to distribute, with excellent stability and shelf-life. Altogether, topical inserts represent a particularly promising form of drug delivery for HIV and STI prevention. Highlighted within this review are end-user acceptability research dedicated to understanding preferred attributes for this form of drug delivery, advantages and disadvantages of the formulation platform options, considerations for their development, clinical assessment of select placebo prototypes, future directions, and the potential impact of this dosage form on the HIV prevention landscape. View Full-Text
Keywords: vaginal drug delivery; rectal drug delivery; HIV; tablets; protection; microbicides; fast-disintegrating; on-demand; extended-release vaginal drug delivery; rectal drug delivery; HIV; tablets; protection; microbicides; fast-disintegrating; on-demand; extended-release
Show Figures

Graphical abstract

MDPI and ACS Style

Peet, M.M.; Agrahari, V.; Anderson, S.M.; Hanif, H.; Singh, O.N.; Thurman, A.R.; Doncel, G.F.; Clark, M.R. Topical Inserts: A Versatile Delivery Form for HIV Prevention. Pharmaceutics 2019, 11, 374.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop